clinical trial · NCT06412848
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·—·completed·n = 360
Urothelial CarcinomaAvelumab
brief summary
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after a platinum-based chemotherapy. This study aims to understand the index date (i.e., at the initiation of avelumab maintenance therapy) demographics and clinical characteristics of participants with locally advanced/metastatic Urothelial Carcinoma in Japan, and to describe their treatment patterns and outcomes.
started
May 9, 2024
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Aug 11, 2026
official title
A Multicenter, Retrospective, Observational Study of Avelumab Maintenance and Subsequent Therapies in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol